drugset / Trial / NCT02058537

Bethanechol for Eosinophilic Esophagitis

NCT02058537 ↗

Phase 2 Terminated 2 enrolled University of Iowa
NaSingle-groupOpen-labelTreatment

Summary

The primary goals of this study are to ease the symptoms of patients with Eosinophilic Esophagitis (EoE) and to test the effectiveness of the drug bethanechol in relieving those symptoms.

Timeline

Start
2014-02
Primary completion
2014-07
Completion
2014-07

Outcome

Outcome not reported

Stopped: “Initial PI left, study not continued”

Drugs

EvaluationDrugModalityDoseRoute
Subject Bethanechol Small molecule 25 mg Oral